Guardant Health, INC Form 4 insider transactions

Guardant Health, Inc. Director Vijaya Gadde has increased her beneficial ownership of common stock by 6,674 shares through the vesting of Restricted Stock Units.

Guardant Health Director Ian T. Clark reported the acquisition of 8,088 shares of common stock through the conversion of restricted stock units, increasing his indirect beneficial ownership.

Guardant Health's Co-Chief Executive Officer, AmirAli Talasaz, sold 119,284 shares of common stock for approximately $5.97 million in early June 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Guardant Health, Inc. Director Meghan V. Joyce reported the scheduled acquisition of 67 shares of common stock through the vesting of restricted stock units on June 4, 2025.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the sale of 4,000 shares of common stock for approximately $185,561 on June 3, 2025.

Guardant Health Director Meghan V. Joyce reported the sale of 100 shares of common stock at $41.66 per share, executed under a Rule 10b5-1 trading plan.

Guardant Health's Chief Legal Officer, John G. Saia, reported the acquisition of 263 common shares through RSU vesting and the disposition of 138 shares for tax withholding purposes.

Guardant Health's Chief Information Officer, Kumud Kalia, reported standard equity transactions including the vesting of Restricted Stock Units and participation in the Employee Stock Purchase Plan, alongside a disposition of shares for tax withholding.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the acquisition of common stock through RSU vesting and subsequent sale of shares to cover tax obligations, alongside an Employee Stock Purchase Plan acquisition.

Guardant Health, Inc. Director Steve E. Krognes reported the acquisition of 154 shares of common stock through the vesting of restricted stock units, increasing his direct beneficial ownership to 10,991 shares.

Director Tariq Musa reported selling 116 shares of Guardant Health, Inc. common stock at $40.04 per share on May 19, 2025.

Director Tariq Musa reports the vesting and conversion of restricted stock units into common stock.

Director Myrtle S. Potter reports a transaction involving Guardant Health, Inc. common stock on May 15, 2025.

Craig Eagle, Chief Medical Officer of Guardant Health, reports the vesting of restricted stock units and subsequent tax withholding.

Darya Chudova, Chief Technology Officer of Guardant Health, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Director Meghan V. Joyce reported the vesting of restricted stock units into 66 shares of Guardant Health, Inc. common stock on May 4, 2025.

AmirAli Talasaz, Co-CEO of Guardant Health, sold shares of the company's common stock on May 1st and 2nd, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Director Steve Krognes reported the vesting of restricted stock units and subsequent acquisition of common stock in Guardant Health, Inc.

Director Tariq Musa sold 116 shares of Guardant Health, Inc. on April 17, 2025, at a price of $44.79 per share.

Director Tariq Musa reports the acquisition and disposal of Guardant Health, Inc. common stock and restricted stock units.

Chief Legal Officer John G. Saia of Guardant Health, Inc. reports the vesting of restricted stock units and subsequent stock sales to cover tax obligations.

Director Myrtle S. Potter reports a transaction involving Guardant Health, Inc. common stock and restricted stock units.

Director Meghan V. Joyce reports the vesting and acquisition of common stock through restricted stock units.

John G. Saia, Chief Legal Officer of Guardant Health, reports transactions involving restricted stock units and common stock.

Kumud Kalia, Chief Information Officer of Guardant Health, reports the vesting and subsequent tax withholding of restricted stock units.

Chris Freeman, Chief Commercial Officer of Guardant Health, reports the vesting and disposal of restricted stock units to cover tax obligations.

Craig Eagle, Chief Medical Officer of Guardant Health, Inc., reports the vesting and tax withholding of restricted stock units.

Darya Chudova, Chief Technology Officer of Guardant Health, reports the vesting and tax withholding of restricted stock units.

Chief Financial Officer of Guardant Health, Michael Bell, reports the vesting of restricted stock units and subsequent stock transactions to cover tax obligations.

Director Steve Krognes reported the vesting and conversion of restricted stock units into common stock of Guardant Health, Inc.